Hamlet Pharma AB (publ): Q3 Interim Report January 2023 – March 2023
Opening remarks During the third quarter of the fiscal year, Hamlet Pharma has continued its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bladder cancer patients. The company has also continued its collaboration with Neurochase for the treatment of brain tumors with Alpha1H. Hamlet Pharma has also successfully completed its Horizon 2020 project, receiving the last part of the grant, which means full funding. The European Commission commended Hamlet Pharma for its progress and stated that the project had fully